PharmaCyte Biotech, Inc. (PMCB) - 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended July 31, 2025. PharmaCyte Biotech, Inc. is a biotechnology company developing cellular therapies for cancer, specifically locally advanced, inoperable pancreatic cancer (LAPC), using its proprietary "Cell-in-a-Box" technology. The company is currently subject to an FDA clinical hold on its Investigational New Drug (IND) application. A reconstituted Board of Directors and a Business Review Committee are currently evaluating the company's strategy, relationships with licensors (SG Austria), and development programs, leading to a curtailment of spending on clinical and pre-clinical activities until the review is complete.
Key Financial Metrics
| Metric | Q1 2025 (Ended July 31) | Q1 2024 (Ended July 31) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(8,360,096) | $23,421,355 (Income) |
| Operating Expenses | $848,305 | $1,268,887 |
| Cash and Cash Equivalents | $13,178,305 | $32,635,092 |
| Total Assets | $45,110,453 | $55,168,353 |
| Total Liabilities | $1,518,865 | $3,277,284 |
| Stockholders' Equity | $43,591,588 | $51,891,069 |
| EPS (Basic & Diluted) | $(1.23) | $1.90 |
Cash Flow: Net cash used in operating activities was $1,993,981 for the quarter, primarily due to the payment of a legal settlement and general administrative expenses. There was no cash flow from investing or financing activities during the quarter.
Material Changes vs. Prior Period
- Net Income to Loss: The company reported a net loss of $8.36 million compared to a net income of $23.42 million in the prior year. The prior year's income was driven by a $21.4 million gain on a related party investment in TNF Pharmaceuticals, which did not recur.
- Investment Valuation: Significant unrealized losses were recorded on investments in TNF Pharmaceuticals (Series G Preferred Stock and Warrants), totaling approximately $7.67 million in fair value adjustments ($2.84M loss on stock, $4.83M loss on warrants).
- Operating Expenses: Total operating expenses decreased by approximately $420,000 (33%) year-over-year, driven by reductions in legal/professional fees and stock-based compensation.
- Liquidity: Cash balances decreased by approximately $2.0 million during the quarter, though the company notes it has approximately $15.7 million in cash as of the filing date due to subsequent financing.
Outlook, Risks, and Unusual Items
- FDA Clinical Hold: The company remains on clinical hold for its LAPC trial. Management is in dialogue with the FDA to potentially forego a large animal study, arguing that existing human clinical trial data for the delivery method supersedes the need for it. The company is awaiting FDA response.
- Strategic Review: Spending on development programs has been curtailed pending the completion of a review by the Business Review Committee regarding the company's relationship with SG Austria (licensor of Cell-in-a-Box technology) and the expiration of licensed patents.
- Subsequent Financing:
- August 2025: Sold Series C convertible preferred stock and warrants for gross proceeds of $7 million.
- September 2025: Agreed to purchase TNF Series H convertible preferred stock and warrants for $3 million.
- Legal Settlement: Settled a breach of contract claim with H.C. Wainwright & Co. for $1.55 million (paid in cash and warrants). An initial payment of $1.25 million was made in May 2025.
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting, specifically regarding insufficient segregation of duties for the CFO and insufficient management review controls.
Investor Verification Checklist
- FDA Status: Verify the current status of the clinical hold and the FDA's response to the request to waive the large animal study.
- SG Austria Relationship: Confirm the outcome of the Business Review Committee's evaluation of the licensing agreement with SG Austria and the status of the expired patents.
- Cash Runway: Assess the sufficiency of the $15.7 million cash balance (including subsequent financing) against the estimated $591,000 in remaining service agreement costs and general operating burn rate.
- Investment Volatility: Review the fair value assumptions (Level 3 inputs) used for the TNF and Femasys investments, as these significantly impact reported earnings.
- Dilution Risk: Evaluate the potential dilution from the recent Series C preferred stock issuance and the outstanding warrant pool (over 19 million warrants).